The nation of Zimbabwe has rejected a substantial US healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years due to Washington's insistence on confidential information.
This move came to light following a government memo from December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the agreement was "lopsided".
A government spokesman has since explained that the United States was requesting biological samples for research and commercial gain while was not willing to guarantee the resulting advantages from any future medical innovations.
"We are forced to start the difficult and regrettable process of ending our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for continued negotiations to reach a deal suitable to both sides so the country's vital HIV programme can be sustained.
Broader Implications
This rejection follows a similar situation in Kenya, where a high court suspended a related deal with the US following legal challenges were raised about the safety of citizens' medical information.
Since returning to office last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had administered aid for the American government, but Trump stated its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to boost openness and accountability.
According to reports, Sixteen African countries have so far agreed to these new agreements, constituting over $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership might have yielded extraordinary advantages for the people of Zimbabwe, especially the 1.2 million presently on HIV treatment via US-supported programmes," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Our nation was requested to share its biological resources and data over an extended period, without any corresponding assurance of benefiting from any medical innovations – such as new medicines or tests – that might be developed from that shared data," he stated.
"In essence, our country would provide the basic resources for medical research without any certainty that the resulting innovations would be accessible to our people if a new disease outbreak arise."
Sovereignty and International Frameworks
He also pointed out that the American exit from the global health body and its pursuit of bilateral health agreements were disrupting frameworks already established through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with future pandemics.
"This system is designed to ensure that when a country provides its data, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to create them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to continued dialogue with our American counterparts on how future co-operation might be arranged in a manner that respects the sovereignty and dignity of both nations."
Health Experts Reaction
Medical experts said it recognised the government's concerns, but suggested that talks need to persist since a large portion of the nation's HIV programmes were funded by external financing.
"If specific concerns arise, such as those relating to information security or agreement terms, these can often be addressed through technical clarification and mutually agreed protections," it said.
The halted deal underscores the ongoing tensions between receiving vital foreign assistance and protecting national sovereignty in an increasingly data-driven world.